Mesenchymal stem cells: immunobiology and role in immunomodulation and tissue regeneration

被引:442
作者
Kode, Jyoti A. [1 ]
Mukherjee, Shayanti [1 ]
Joglekar, Mugdha V. [2 ]
Hardikar, Anandwardhan A. [2 ]
机构
[1] Tata Mem Hosp, Chiplunkar Lab, ACTREC, Kharghar 410210, Navi Mumbai, India
[2] Natl Ctr Cell Sci, Stem Cells & Diabet Sect, Lab 12, Pune, Maharashtra, India
关键词
Cell therapy; immunobiology; immunomodulation; mesenchymal stem cells; tissue regeneration; MARROW STROMAL CELLS; VERSUS-HOST-DISEASE; BONE MORPHOGENETIC PROTEINS; ENDOTHELIAL GROWTH-FACTOR; TOLL-LIKE RECEPTORS; IN-VITRO; PROGENITOR CELLS; MYOCARDIAL-INFARCTION; COSTIMULATORY PATHWAY; THERAPEUTIC STRATEGY;
D O I
10.1080/14653240903080367
中图分类号
Q813 [细胞工程];
学科分类号
100113 [医学细胞生物学];
摘要
Mesenchymal stem cells ( MSC) are multipotent cells that differentiate into osteoblasts, myocytes, chondrocytes and adipocytes as well as insulin-producing cells. The mechanism underlying their in vivo differentiation is not clear and is thought to be caused by spontaneous cell fusion or factors present in the microenvironment. However, their ease of isolation, high 'ex-vivo' expansion potential and ability to differentiate into multiple lineages make them attractive tools for potential use in cell therapy. MSC have been isolated from several tissues, including bone/bone marrow, fat, Wharton's jelly, umbilical cord blood, placenta and pancreas. The 'immunosuppressive' property of human MSC makes them an important candidate for cellular therapy in allogeneic settings. Use of allogeneic MSC for repair of large defects may be an alternative to autologous and allogeneic tissue-grafting procedures. An allogeneic approach would enable MSC to be isolated from any donor, expanded and cryopreserved, providing a readily available source of progenitors for cell replacement therapy.
引用
收藏
页码:377 / 391
页数:15
相关论文
共 93 条
[1]
Improvement of porous β-TCP scaffolds with rhBMP-2 chitosan carrier film for bone tissue application [J].
Abarrategi, Ander ;
Moreno-Vicente, Carolina ;
Ramos, Viviana ;
Aranaz, Inmaculada ;
Sanz Casado, Jose Vicente ;
Lopez-Lacomba, Jose Luis .
TISSUE ENGINEERING PART A, 2008, 14 (08) :1305-1319
[2]
Immunomodulation by mesenchymal stem cells - A potential therapeutic strategy for type 1 diabetes [J].
Abdi, Reza ;
Fiorina, Paolo ;
Adra, Chaker N. ;
Atkinson, Mark ;
Sayegh, Mohamed H. .
DIABETES, 2008, 57 (07) :1759-1767
[3]
Alhadlaq A, 2004, STEM CELLS DEV, V13, P436, DOI 10.1089/scd.2004.13.436
[4]
Allogeneic mesenchymal stem cells regenerate bone in a critical-sized canine segmental defect [J].
Arinzeh, TL ;
Peter, SJ ;
Archambault, MP ;
van den Bos, C ;
Gordon, S ;
Kraus, K ;
Smith, A ;
Kadiyala, S .
JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME, 2003, 85A (10) :1927-1935
[5]
Beyer Nardi N, 2006, HANDB EXP PHARM, V174, P249
[6]
Chromosome variability of human multipotent mesenchymal stromal cells [J].
Bochkov, N. P. ;
Voronina, E. S. ;
Kosyakova, N. V. ;
Liehr, T. ;
Rzhaninova, A. A. ;
Katosova, L. A. ;
Platonova, V. I. ;
Gol'dshtein, D. V. .
BULLETIN OF EXPERIMENTAL BIOLOGY AND MEDICINE, 2007, 143 (01) :122-126
[7]
MESENCHYMAL STEM-CELLS [J].
CAPLAN, AI .
JOURNAL OF ORTHOPAEDIC RESEARCH, 1991, 9 (05) :641-650
[8]
Adult mesenchymal stem cells for tissue engineering versus regenerative medicine [J].
Caplan, Arnold I. .
JOURNAL OF CELLULAR PHYSIOLOGY, 2007, 213 (02) :341-347
[9]
Concise review: Mesenchymal stem cells: Their phenotype, differentiation capacity, immunological features, and potential for homing [J].
Chamberlain, Giselle ;
Fox, James ;
Ashton, Brian ;
Middleton, Jim .
STEM CELLS, 2007, 25 (11) :2739-2749
[10]
Conget PA, 1999, J CELL PHYSIOL, V181, P67, DOI 10.1002/(SICI)1097-4652(199910)181:1<67::AID-JCP7>3.3.CO